Invalid Symbol

Stock Research for CTIC

CTIC
Current Price

$


Latest Update:

High
$
Low
$
Close
$
Volume
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

CTIC Stock Chart & Research Data

The CTIC chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CTIC chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CTIC Due diligence Resources & Stock Charts

The CTIC stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CTIC Detailed Price Forecast - CNN Money CNN View CTIC Detailed Summary - Google Finance
Yahoo View CTIC Detailed Summary - Yahoo! Finance Zacks View CTIC Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View CTIC Trends & Analysis - Trade-Ideas Barrons View CTIC Major Holders - Barrons
NASDAQ View CTIC Call Transcripts - NASDAQ Seeking View CTIC Breaking News & Analysis - Seeking Alpha
Spotlight View CTIC Annual Report - CompanySpotlight.com OTC Report View CTIC OTC Short Report - OTCShortReport.com
TradeKing View CTIC Fundamentals - TradeKing Charts View CTIC SEC Filings - Bar Chart
WSJ View Historical Prices for CTIC - The WSJ Morningstar View Performance/Total Return for CTIC - Morningstar
MarketWatch View the Analyst Estimates for CTIC - MarketWatch CNBC View the Earnings History for CTIC - CNBC
StockMarketWatch View the CTIC Earnings - StockMarketWatch MacroAxis View CTIC Buy or Sell Recommendations - MacroAxis
Bullish View the CTIC Bullish Patterns - American Bulls Short Pains View CTIC Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View CTIC Stock Mentions - StockTwits PennyStocks View CTIC Stock Mentions - PennyStockTweets
Twitter View CTIC Stock Mentions - Twitter Invest Hub View CTIC Investment Forum News - Investor Hub
Yahoo View CTIC Stock Mentions - Yahoo! Message Board Seeking Alpha View CTIC Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for CTIC - SECform4.com Insider Cow View Insider Transactions for CTIC - Insider Cow
CNBC View CTIC Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CTIC - OTC Markets
Yahoo View Insider Transactions for CTIC - Yahoo! Finance NASDAQ View Institutional Holdings for CTIC - NASDAQ


Stock Charts

FinViz View CTIC Stock Insight & Charts - FinViz.com StockCharts View CTIC Investment Charts - StockCharts.com
BarChart View CTIC Stock Overview & Charts - BarChart Trading View View CTIC User Generated Charts - Trading View


Latest Financial News for CTIC

CTI BioPharma to Present at the 7th Annual Leerink Partners Global Healthcare Conference
Posted on Wednesday February 14, 2018

SEATTLE , Feb. 14, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present at the 7 th Annual Leerink Partners Global Healthcare Conference ...


CTI BioPharma Announces Closing Of Underwritten Public Offering Of Common Stock
Posted on Tuesday February 13, 2018

SEATTLE, Feb. 13, 2018 /PRNewswire/ -- CTI BioPharma Corp. ("CTI BioPharma") (CTIC) today announced the closing of its previously announced underwritten public offering of 20,000,000 shares of its common stock, at a public offering price of $3.00 per share of common stock. In addition, the underwriters exercised in full their option to purchase 3,000,000 additional shares of common stock at the public offering price, less the underwriting discount. The expected proceeds to CTI BioPharma from the offering are approximately $64.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by CTI BioPharma.


CTI BioPharma Prices Underwritten Public Offering of $60 Million of Common Stock
Posted on Friday February 09, 2018

SEATTLE, Feb. 9, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (CTIC) today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock, at a public offering price of $3.00 per share of common stock. In addition, CTI BioPharma has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of common stock at the public offering price, less the underwriting discount. Proceeds to CTI BioPharma from the offering are expected to be $55.8 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by CTI BioPharma.


CTI BioPharma Announces Launch of Follow-On Offering
Posted on Monday February 05, 2018

SEATTLE, Feb. 5, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (CTIC) today announced the launch of a proposed underwritten public offering of shares of its common stock. In addition, CTI BioPharma expects to grant the underwriters a 30-day option to purchase additional shares of its common stock. The Company intends to use the net proceeds of the offering to complete the PAC203 clinical trial, complete the review of the pacritinib MAA by the EMA, conduct additional research concerning the possible application of pacritinib in indications outside of myelofibrosis, and complete the PIX306 clinical trial, as well as for general corporate purposes, which may include funding research and development, conducting preclinical and clinical trials, acquiring or in-licensing potential new pipeline candidates, preparing and filing possible new drug applications and general working capital.


CTI BioPharma Announces Closing Of Underwritten Public Offering Of Common Stock
PR Newswire (press release) - Feb 13, 2018
The expected proceeds to CTI BioPharma from the offering are approximately $64.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by CTI BioPharma. CTI BioPharma plans to use the net proceeds ...
Today Analysts Focus on NVIDIA Corporation (NVDA), CTI BioPharma Corp. (CTIC) - StockNewsJournal
Investors Jumping Ship on CTI BioPharma Corp. (CTIC), Progenics ... - Post Analyst

CTI BioPharma Announces Launch of Follow-On Offering
PR Newswire (press release) - Feb 5, 2018
SEATTLE, Feb. 5, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced the launch of a proposed underwritten public offering of shares of its common stock.
Otonomy, Inc. (OTIC) Reaches $5.63 After 8.00% Up Move; Cti Biopharma (CTIC ... - Thorold News

CTI BioPharma to Present at the 7th Annual Leerink Partners Global Healthcare ...
PR Newswire (press release) - Feb 14, 2018
SEATTLE, Feb. 14, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present at the 7th Annual Leerink Partners Global Healthcare Conference in New York, NY on Thursday, February 15, 2018 at 2 ...
Taking A Longer Viewpoint Of CTI BioPharma Corp. (CTIC), Delek US Holdings ... - Post Analyst
Worth Watching Stocks: CTI BioPharma Corp. (NASDAQ:CTIC), Flexion Therapeutics ... - The Oracle Examiner

CTI BioPharma Loses Strength As The Company Faces Sharp Revenue Decline
Seeking Alpha - Dec 20, 2017
CTI BioPharma Corp. (NASDAQ:CTIC) stock showed a steady decline this year, on the back of several setbacks suffered by the company.

Enter a stock symbol to view the stock details.